会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • SIR2 Activity
    • SIR2活动
    • US20100105036A1
    • 2010-04-29
    • US12408575
    • 2009-03-20
    • Leonard GuarenteHomayoun VaziriShin-Ichiro Imai
    • Leonard GuarenteHomayoun VaziriShin-Ichiro Imai
    • C12Q1/68G01N33/53
    • C12Q1/68C12Q1/44G01N2333/4703G01N2333/916G01N2500/02
    • This invention relates to methods of screening compounds that modulate cellular and organismal processes by modification of the activity of SIR2 and/or transcription factors, e.g., p53, particularly methods of screening for compounds that modify lifespan and/or metabolism of a cell or an organism by modulation of the activity of SIR2 and/or transcription factors, e.g., p53, and more particularly to methods of screening for compounds that modulate the activity of Sir2 and/or transcription factors, e.g., p53. In particular, the present invention relates to a method for screening a compound, by providing a test mixture comprising a transcription factor, Sir2, and a Sir2 cofactor with the compound, and evaluating an activity of a component of the test mixture in the presence of the compound. The invention further relates to therapeutic uses of said compounds. The invention further relates to a method of modifying the acetylation status of a transcription factor binding site on histone or DNA by raising local concentrations of Sir2.
    • 本发明涉及通过修饰SIR2和/或转录因子活性(例如p53)来筛选调节细胞和生物体过程的化合物的方法,特别是筛选修饰细胞或生物体的寿命和/或代谢的化合物的方法 通过调节SIR2和/或转录因子例如p53的活性,更具体地涉及筛选调节Sir2和/或转录因子例如p53的活性的化合物的方法。 特别地,本发明涉及通过提供包含转录因子Sir2和Sir2辅因子与该化合物的测试混合物来筛选化合物的方法,并且在存在下评价测试混合物的组分的活性 化合物。 本发明还涉及所述化合物的治疗用途。 本发明还涉及通过提高Sir2的局部浓度来改变组蛋白或DNA上的转录因子结合位点的乙酰化状态的方法。
    • 6. 发明申请
    • Method of extending life span
    • 延长寿命的方法
    • US20050164969A1
    • 2005-07-28
    • US10993903
    • 2004-11-19
    • Gil BlanderLeonard Guarente
    • Gil BlanderLeonard Guarente
    • A61K48/00C07H21/04C07K14/47C12N9/18
    • C12N9/18C07K14/4746
    • The present invention provides new and advantageous methods, compositions, cell constructs and animal models related to inhibiting the senescence of vertebrate cells and vertebrate organisms based on the use of SIRT1 polynucleotides and polypeptides, as well as mutant SIRT1 polynucleotides and polypeptides. The invention provides polynucleotides that encode variants and fragments of SIRT1 polypeptides, and also provides variant SIRT1 polypeptides and fragments thereof. Additionally the invention provides a method of inhibiting or delaying the expression in a vertebrate cell of a protein having biological activity associated with loss of population doubling in the cell. The invention further provides a method of treating a pathology, a disease or a medical condition in a subject, wherein the pathology responds to an SIRT1 polypeptide. The invention also provides a vertebrate cell that incorporates a heterologous nucleic acid encoding a variant of SIRT1, or a fragment thereof, as well as a transgenic mammal a majority of whose cells harbor a transgene including a nucleic acid sequence encoding an SIRT1 polypeptide. The invention also provides an antibody that binds immunospecifically to a variant SIRT1 polypeptide or a fragment thereof, and a method of determining whether the amount of an SIRT1 polypeptide in a sample differs from the amount of the SIRT1 polypeptide in a reference. The invention further provides a method of contributing to the diagnosis or prognosis of, or to developing a therapeutic strategy for, a disease or pathology in a subject, wherein the disease or pathology responds to treatment with an SIRT1 polypeptide and wherein the amount of SIRT1 polypeptide in the pathology is known to differ from the amount of the SIRT1 polypeptide in a nonpathological state.
    • 本发明提供了基于使用SIRT1多核苷酸和多肽以及突变型SIRT1多核苷酸和多肽来抑制脊椎动物细胞和脊椎动物生物衰老有关的新的和有利的方法,组合物,细胞构建体和动物模型。 本发明提供编码SIRT1多肽的变体和片段的多核苷酸,并且还提供变体SIRT1多肽及其片段。 另外,本发明提供了抑制或延迟具有生物活性的蛋白质的脊椎动物细胞中表达的方法,所述生物活性与细胞中群体倍增的丧失相关。 本发明还提供了治疗受试者的病理学,疾病或医学病症的方法,其中所述病理学响应于SIRT1多肽。 本发明还提供了一种脊椎动物细胞,其包含编码SIRT1的变体或其片段的异源核酸,以及转基因哺乳动物,其大部分细胞含有包含编码SIRT1多肽的核酸序列的转基因。 本发明还提供了与变体SIRT1多肽或其片段免疫特异性结合的抗体,以及确定样品中SIRT1多肽的量是否与参考文献中SIRT1多肽的量不同的方法。 本发明进一步提供了一种有助于对受试者的疾病或病理学的诊断或预后或制定治疗策略的方法,其中所述疾病或病理学响应于SIRT1多肽的治疗,并且其中SIRT1多肽的量 在病理学中已知与非病理状态下SIRT1多肽的量不同。